Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials

This video explores the development of EMACC and its advantages in assessing cognitive changes over time in early Alzheimer’s Disease (AD) patients. It will also cover the regulatory landscape for Alzheimer’s disease drug development and the role of the CDR-SB clinical scale. Speakers include Dr. Judith Jaeger, President of CognitionMetrics and leader of the team that developed and validated EMACC, Dr. Sarah Barnum, and CJ Barnum, VP of CNS Drug Development at INmune Bio.
EMACC has incredible potential to improve AD clinical development by improving assessment of cognitive changes. This will lead to smaller, shorter clinical trials, which means less burden on both patients and investors in terms of time and money.
#alzheimer #podcast #interview #alzheimersdisease #alzheimersresearch #clinical #neuromedicine #neuroscience #cognitivedecline #cognition #xpro1595 #inmune #clinicaltrial #clinicaltrials #biotechnology #biotech #biotechinnovation